Cagrilintide

What is Cagrilintide?#

Cagrilintide (development codes NN9838 and ZP4982) is a long-acting analog of human amylin (also known as islet amyloid polypeptide, or IAPP) developed by Novo Nordisk for the treatment of obesity. Amylin is a 37-amino acid peptide hormone co-secreted with insulin by pancreatic beta cells in response to nutrient intake. It plays a physiological role in regulating appetite, gastric emptying, and postprandial glucose metabolism.

The native amylin peptide has an extremely short plasma half-life of approximately 13 minutes and is prone to aggregation and fibrillation, making it unsuitable for therapeutic use in its unmodified form. Cagrilintide was engineered to overcome these limitations through strategic amino acid modifications and acylation with a C18 fatty diacid side chain that enables non-covalent albumin binding, extending the half-life to approximately 7 days and allowing once-weekly subcutaneous dosing.

Cagrilintide represents a new therapeutic approach to obesity that is distinct from and complementary to the GLP-1 receptor agonist class (which includes semaglutide and liraglutide). While GLP-1 agonists primarily act on the GLP-1 receptor in the brain and gut, cagrilintide acts through amylin receptors (AMY1 and AMY3) and calcitonin receptors, engaging different neuronal circuits involved in appetite regulation. This mechanistic complementarity forms the basis for the CagriSema combination program, which pairs cagrilintide with semaglutide.

Mechanism of Action#

Cagrilintide exerts its pharmacological effects through activation of amylin receptors and calcitonin receptors in the central nervous system and peripheral tissues. Amylin receptors are heterodimeric complexes formed by the calcitonin receptor (CTR) with receptor activity-modifying proteins (RAMPs). The AMY1 receptor (CTR plus RAMP1), AMY3 receptor (CTR plus RAMP3), and the calcitonin receptor itself are the primary targets.

The central mechanism of appetite suppression involves activation of neurons in the area postrema and nucleus of the solitary tract in the brainstem, regions that are accessible to circulating peptides due to their location outside the blood-brain barrier. Activation of amylin receptors in these regions produces signals of meal termination and satiety, reducing meal size and overall food intake.

Additional mechanisms include slowing of gastric emptying, which prolongs gastric distension signals and contributes to postprandial satiety. Amylin receptor activation also suppresses postprandial glucagon secretion, contributing to improved glucose homeostasis. In preclinical models, amylin analogs have been shown to reduce food reward signaling and alter food preference toward less energy-dense options.

The signaling pathways downstream of amylin receptor activation involve cyclic AMP generation, intracellular calcium mobilization, and activation of the ERK1/2 MAP kinase pathway. The relative contribution of each receptor subtype (AMY1, AMY3, CTR) to the appetite-suppressing effects of cagrilintide is an area of active research.

Clinical Development#

Cagrilintide has been evaluated in multiple clinical trials as both a standalone therapy and in combination with semaglutide. The phase 2 dose-finding study (published in The Lancet, 2021) demonstrated dose-dependent weight loss with cagrilintide monotherapy, with the highest dose group (4.5 mg weekly) achieving approximately 10.8% body weight loss over 26 weeks compared to 3.0% with placebo.

The most significant clinical development is the CagriSema program, which combines cagrilintide with semaglutide 2.4 mg in a single once-weekly injection. The rationale for this combination is the mechanistic complementarity between amylin receptor agonism and GLP-1 receptor agonism, which engage distinct but converging appetite-regulatory pathways. Phase 3 trials of CagriSema have demonstrated weight loss exceeding that achieved by semaglutide alone, with results suggesting the combination may approach the efficacy of more aggressive surgical interventions.

CagriSema Combination#

The CagriSema combination represents the most advanced clinical application of cagrilintide. By combining two peptide hormones with complementary mechanisms of action, CagriSema targets a broader range of appetite-regulatory circuits than either agent alone. The GLP-1 component (semaglutide) provides potent appetite suppression through GLP-1 receptor activation in hypothalamic and hindbrain circuits, while the amylin component (cagrilintide) adds independent appetite suppression through amylin receptor activation in the area postrema.

Clinical trial results have demonstrated that the weight loss achieved with CagriSema exceeds the additive effect of the individual components, suggesting a synergistic interaction between the two pathways. This synergy may reflect the convergence of GLP-1 and amylin signaling on shared downstream neuronal circuits involved in energy balance regulation.

Research Overview#

The evidence base for cagrilintide is robust relative to many investigational peptides, with published phase 2 and phase 3 clinical trial data in peer-reviewed journals. The clinical development program has included studies in diverse populations including individuals with obesity, individuals with type 2 diabetes, and individuals with both conditions. The published studies provide direct evidence of efficacy for weight loss and generally favorable tolerability, with gastrointestinal side effects being the most common adverse events.

The evidence quality is classified as moderate to high, reflecting the availability of randomized, placebo-controlled clinical trial data from well-designed studies with appropriate endpoints. Key limitations include the relatively short duration of completed studies, the absence of long-term safety data beyond 2 years, and the limited data on cardiovascular outcomes.

Important Considerations#

Cagrilintide is an investigational compound that has not yet received regulatory approval from the FDA or EMA as a standalone product. CagriSema (the combination with semaglutide) is in advanced clinical development. All use outside of clinical trials is investigational. The gastrointestinal side effect profile, including nausea and vomiting, is clinically significant and requires careful dose titration. Individuals with a history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or pancreatitis should not use amylin analogs or GLP-1 receptor agonists without careful evaluation of the risk-benefit ratio.

Key Research Findings#

Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial, published in The Lancet (Lau DCW et al., 2021; PMID: 34798060):

• The study showed cagrilintide monotherapy produced dose dependent weight loss up to 10.8% at 4.5 mg weekly over 26 weeks

Related Reading#

• Cagrilintide research studies and evidence
• Cagrilintide dosing protocols
• Cagrilintide side effects profile
• Adipotide research guide
• GUBamy research guide